Skip to main content
TipRanks
Go Ultimate75% OFF

Centene (CNC) AI Stock Analysis

3,075 Followers
CNC

Centene

(NYSE:CNC)

Select Model
Rating:67Neutral
Price Target:$82.00â–²(9.67% Upside)
Action:reiterated
Date:11/05/26

The score is driven primarily by mixed financial performance—strong revenue and generally supportive cash generation, but notable earnings/ROE volatility. Technicals are a meaningful positive with the stock in a strong uptrend. The latest earnings call adds support via raised guidance and operational improvements, while valuation is a modest drag given a P/E that looks high relative to profitability consistency.

Positive Factors
Strong Revenue GrowthRapid revenue expansion demonstrates strong demand across Centene’s government-sponsored and Marketplace businesses. Continued top-line growth can broaden operating scale, support investment in care-management capabilities, and provide a durable base for improving earnings if medical costs remain controlled.
Negative Factors
Volatile, Thin ProfitabilityProfitability has not yet demonstrated consistent durability despite strong revenue growth. The 2025 loss and low TTM operating margin indicate that medical utilization, execution, or other cost pressures can quickly erode earnings and limit the conversion of scale into shareholder returns.

Centene Key Performance Indicators (KPIs)

Revenue by SegmentAnalyzes income from different business segments, revealing which areas are most profitable and where the company might expand or face challenges.

$0.00$10.00B$20.00B$30.00B$40.00B$50.00BSep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Medicaid and Medicare have become the growth drivers: Medicaid revenue climbs despite declining membership because mid‑year state rate actions and premium pass‑throughs are boosting dollars per member, while Medicare (PDP) shows a pronounced ramp as premium scale and favorable 2025 settlements lift revenue and margins. Commercial peaked in 2025 and has softened into 2026, consistent with Marketplace pressure and seasonality. Management warned some Q2 upside was nonrecurring, so focus on sustainable margin trends and membership/acuity risk when modeling forward earnings.

Data provided by:The Fly

Centene (CNC) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%CNC+114.67%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$37.02B
Dividend Yield
―
Average Volume (3M)
4.88M
Price to Earnings (P/E)
25.3
Beta (1Y)
0.40
Revenue Growth
9.71%
EPS Growth
―
Country
US
Employees
61,100
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Centene Business Overview & Revenue Model

Company Description

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The...

How the Company Makes Money

Centene makes money primarily by operating managed care health plans and administering benefits for government-sponsored healthcare programs. Its largest revenue stream comes from premium revenue and capitation payments: state Medicaid agencies and t...

Centene Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:9.91%|Next Earnings Date:Feb 09, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Centene delivered a better-than-expected third quarter, raised 2026 adjusted EPS guidance from more than $4.80 to more than $5.20, reported strong Medicare and Marketplace performance, reached an earlier-than-expected Medicare Advantage breakeven target, reduced debt, and described multiple operating and cost-management improvements. The primary challenges were Medicaid membership declines and work-requirement-related acuity risks, expected Medicare Advantage membership contraction, Marketplace membership attrition and program-integrity costs, the planned commercial-group exit, and a likely PDP margin reset in 2027. Highlights significantly outweighed the lowlights.

Positive Updates

Third-Quarter Earnings Beat and Raised 2026 Outlook
Centene reported third-quarter adjusted diluted EPS of $0.58, ahead of previous expectations, on $45.1 billion in premium and service revenue. Consolidated HBR was 92.7%, better than expected, and full-year 2026 adjusted diluted EPS guidance was raised to more than $5.20 from more than $4.80. The improved outlook was attributed to continued Medicare strength, Marketplace pretax margin moving to the top of the prior 4.5% to 5.0% range, and lower interest expense with a midpoint of $610 million.

Negative Updates

Medicaid Membership Decline and Eligibility Headwinds
Medicaid ended the quarter with 11.9 million members, down 5.0% year to date. Centene expects full-year 2026 Medicaid membership to be down approximately 8% to 9% versus year-end 2025, with additional Q4 reductions tied to Florida CMS membership rolling off, OB3 eligibility terminations for legal noncitizens, and at least one state beginning work requirements.

Company Guidance

Centene raised 2026 adjusted diluted EPS guidance to >$5.20, with a full-year Medicaid HBR of approximately 93.5%, Medicaid membership down 8% to 9% year over year, a composite Medicaid rate of ~5%, Medicare Advantage reaching breakeven, PDP pretax margins in the mid- to high 3s, Marketplace pretax margin at the top of the previous 4.5% to 5.0% range, year-end Marketplace membership around 3.2 million, a full-year SG&A ratio midpoint of 7.2%, approximately $1.5 billion of investment and other income, and interest expense at a midpoint of $610 million; for 2027, the company expects to grow adjusted EPS relative to both the $4.70 jump off point and the revised $5.20 2026 guidance, with slight improvement in Medicaid HBR, Medicare Advantage better than breakeven, PDP membership growth, an improved SG&A rate, Medicaid membership attrition from OB 3, Medicare Advantage membership down year over year, Marketplace slight contraction, and an opening PDP margin expectation probably somewhere in 2% to 3% range.

Centene Financial Statement Overview

Summary

Strong revenue momentum and generally positive free cash flow support the core financial profile, and leverage appears manageable. However, profitability has been highly volatile (loss in 2025 followed by partial recovery), ROE remains negative in TTM, and cash flow has shown meaningful year-to-year swings—raising execution and medical cost/utilization risk.

Income Statement

52Neutral

Balance Sheet

58Neutral

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue203.90B194.78B163.07B154.00B144.55B125.98B
Gross Profit41.15B23.83B16.83B17.32B16.66B14.20B
EBITDA3.78B-5.14B6.20B5.62B4.18B3.95B
Net Income1.46B-6.67B3.31B2.70B1.20B1.35B
Balance Sheet
Total Assets79.28B76.75B82.44B84.64B76.87B78.38B
Cash, Cash Equivalents and Short-Term Investments23.59B20.32B16.68B19.65B14.39B14.66B
Total Debt15.54B18.16B19.43B18.88B21.33B22.66B
Total Liabilities56.97B56.69B55.94B58.69B52.63B51.35B
Stockholders Equity22.21B19.95B26.41B25.84B24.06B26.80B
Cash Flow
Free Cash Flow3.96B4.32B-490.00M7.25B5.26B3.29B
Operating Cash Flow4.74B5.09B154.00M8.05B6.26B4.21B
Investing Cash Flow1.31B453.00M-1.05B-1.28B-2.92B-3.30B
Financing Cash Flow-2.09B-1.60B-2.41B-1.57B-4.20B1.36B

Centene Technical Analysis

Technical Analysis SentimentPositive
Last Price74.77

Price Trends

50DMA67.23Positive
100DMA66.38Positive
200DMA56.79Positive

Market Momentum

MACD1.32Negative
RSI61.98Neutral
STOCH50.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNC, the sentiment is Positive. The current price of 74.77 is above the 20-day moving average (MA) of 70.14, above the 50-day MA of 67.23, and above the 200-day MA of 56.79, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 61.98 is Neutral, neither overbought nor oversold. The STOCH value of 50.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNC.

Centene Risk Analysis

Centene disclosed 34 risk factors in its most recent earnings report. Centene reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The imposition of tariffs by the U.S. government and any retaliatory tariffs imposed in response could have a material adverse effect on our results of operations, financial condition and cash flows.Q1, 2025
2.Significant changes or judicial challenges to the ACA and the other government-sponsored healthcare programs in which we participate could materially and adversely affect our results of operations, financial condition, and cash flows.Q4, 2024
3.Negative public perception of the managed care industry, including industry practices, could adversely affect our business, operating results, cash flows and prospects.Q4, 2024

Centene Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CNC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
OSCROSCR77Outperform$9.67B11.1249.48%―54.77%―
ELVELV76Outperform$96.42B18.9711.59%1.54%3.60%-4.06%
CICI75Outperform$79.09B13.1814.10%2.06%6.79%-0.38%
CNCCNC67Neutral$37.02B25.266.78%―9.71%―
HUMHUM58Neutral$55.40B44.416.70%0.77%22.02%-3.07%
MOHMOH53Neutral$12.17B-377.95-1.17%―-0.95%-105.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%CNCCIHUMMOHELVOSCRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CNC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CNCCentene74.7738.82107.98%
CICigna300.1634.2012.86%
HUMHumana461.25235.30104.14%
MOHMolina Healthcare Inc233.0994.9768.76%
ELVElevance Health, Inc.446.28136.0843.87%
OSCROscar Health, Inc.31.3317.25122.51%

Centene Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Centene Redeems Remaining 2027 Notes to Simplify Debt

Positive
Oct 8, 2026

On October 8, 2026, Centene Corporation announced it had notified holders of its intention to redeem on October 23, 2026 all of the remaining $568.664 million principal amount of its outstanding 4.25% notes due December 15, 2027. The redemption will...

Business Operations and StrategyFinancial Disclosures

Centene Reaffirms 2026 Earnings Guidance at Healthcare Summit

Positive
Sep 16, 2026

Centene Corporation said it will participate in the Deutsche Bank 2026 Healthcare Summit on September 16, 2026, where management plans to discuss business performance and financial results. The company will reaffirm its full-year 2026 guidance for GA...

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

Centene Announces Planned Chief Financial Officer Transition

Neutral
Aug 17, 2026

On August 17, 2026, Centene announced a planned chief financial officer transition, with current CFO Drew Asher set to step down from the role on December 31, 2026 and retire from the company at the end of 2027, while remaining as a strategic advisor...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026